ArticleNeuro-oncology advances

Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma.

Benjamin M Ellingson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.